Health Discovery Corporation (OTCMKTS: HDVY) is spiking up the charts on a significant surge of volume in recent days after the Company announced it has filed an infringement lawsuit against Intel Corporation pertaining to HDC ’s Support Vector Machine-Recursive Feature Elimination methods (“SVM-RFE”) patents. Health Discovery has attempted numerous times to avoid litigation with Intel regarding this dispute. Unfortunately, those efforts were unsuccessful and as a result this infringement suit is necessary according to HDC CEO George H. McGovern, III.
Patent stocks are even more explosive than biotechs and HDVY has been no exception spiking from under a penny to highs over $0.20 per share in February of last year after the United States Patent and Trademark Office (“USPTO”) ruled in favor of HDC on the SVM-RFE Patents in the Interference proceeding between HDC and Intel. HDC has retained the firm of Dunlap, Bennett & Ludwig to represent the Company which has been filed in the United States District Court for the Western District of Texas, Waco Division where Intel has operations.
Health Discovery Corporation (OTCMKTS: HDVY) is a machine learning company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery. The terms artificial intelligence and machine learning are sometimes used to describe pattern recognition tools.
HDC’s mission is to use its patents, intellectual prowess, and clinical partnerships principally to identify patterns that can advance the science of medicine, as well as to advance the effective use of its technology in other diverse business disciplines, including the high-tech, financial, and healthcare technology markets.
The Companies historical foundation lies in the molecular diagnostics field where it haas made a number of discoveries that may play a role in developing more personalized approaches to the diagnosis and treatment of certain diseases. However, its Support Vector Machines (“SVM”) assets in particular have broad applicability in many other fields. Intelligently applied, HDC’s pattern recognition technology can be a portal between enormous amounts of otherwise undecipherable data and truly meaningful discovery.
HDC principal asset is its intellectual property, which includes advanced mathematical algorithms called SVM, as well as biomarkers that it discovered by applying its SVM techniques to complex genetic and proteomic data. HDI intellectual property is protected by 31 patents that have been issued or are currently pending around the world.
To Find out the inside Scoop on HDVY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
HDC is surging higher after the Company announced it has filed an infringement lawsuit against Intel Corporation. This infringement suit pertains to Health Discovery’s Support Vector Machine-Recursive Feature Elimination methods (“SVM-RFE”) patents.
In February 2019 HDVY skyrocketed from under a penny to highs over $0.20 per share after the United States Patent and Trademark Office (“USPTO”) ruled in favor of Health Discovery on the SVM-RFE Patents in the Interference proceeding between HDC and Intel. The Patent Trial and Appeal Board (“PTAB”) of the USPTO issued its decision, finding that Health Discovery is entitled to claim exclusive rights to the SVM-RFE technology as set forth in the patent application that was filed to provoke the Interference. The decision ordered Intel’s Patent No. 7,685,077 to be cancelled. The decision also dismissed Intel’s motions challenging the validity of Health Discovery’s pending claims and issued patents covering SVM-RFE.
In September 2019, the USPTO issued U.S. Patent No. 10,402,685 (“SVM-RFE Patent”) for Health Discovery’s patent application covering SVM-RFE. Health Discovery now owns four patents in the United States, owns five international patents covering the SVM-RFE method, and is the sole owner of all patents related to SVM-RFE. Furthermore, the USPTO granted a Patent Term Adjustment (“PTA”) to the SVM-RFE Patent. The PTA is 1,785 days (almost 5 years), which, added to the normal 20-year-from-filing patent term, extends this patent term to June 7, 2025.
George H. McGovern, III, HDC’s Chairman and CEO, noted, “Health Discovery is taking the necessary steps to protect its sole ownership of SVM-RFE patents against infringement.”
Very cheap shares to buy at .06 should be trading over .70+ with lawsuithttps://t.co/KFFdV063uP
— Pro_Stock_Trader (@_ProStockTrader) July 24, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Currently running up the charts HDVY is an exciting story developing in small caps; pink current, the Company has over $2 million in the treasury and its most valuable asset i its intellectual property, which includes advanced mathematical algorithms called SVM, as well as biomarkers that it discovered by applying its SVM techniques to complex genetic and proteomic data. HDI intellectual property is protected by 31 patents that have been issued or are currently pending around the world. The Company scored a resounding win in February 2019 when the USPTO ruled in favor of HDC on the SVM-RFE Patents in the Interference proceeding between HDC and Intel. Now that HDC has filed a lawsuit things could start popping for HDVY. Intel has paid out big money to settle patent-infringement lawsuit’s in the past recently paying $250 million over five years to Transmeta Corp. to settle a patent-infringement lawsuit over chip designs and power management technology Patent stocks are even more explosive than biotechs, we have covered another play in the space NLST as it has risen from pennies to highs near $1. We will be updating on HDVY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HDVY.
WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?
Disclosure: we hold no position in HDVY either long or short and we have not been compensated for this article.